Lexeo Therapeutics, Inc. Common Stock Income Statement
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
2023
2022
2021
2020
0M
-100.00%
0M
0M
69M
15M
53M
-69M
0M
-66M
0M
-66M
12.01%
0M
3M
0M
2M
0M
1M
-60.53%
0M
1M
61M
12M
49M
-61M
0M
-59M
0M
-59M
17.10%
61M
1M
-58M
1M
-59M
2M
219.59%
0M
2M
52M
7M
45M
-51M
0M
-51M
0M
-51M
882.42%
52M
0M
-51M
0M
-51M
1M
-
0M
1M
5M
1M
4M
-5M
0M
-5M
0M
-5M
882.42%
5M
0M
-5M
0M
-5M
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
4Q2023
3Q2023
2Q2023
4Q2022
3Q2022
2Q2022
0M
-100.00%
0M
0M
15M
7M
8M
-15M
0M
-14M
0M
-14M
-16.82%
15M
1M
-13M
0M
-14M
0M
-100.00%
0M
0M
20M
3M
17M
-20M
0M
-20M
0M
-20M
32.79%
20M
0M
-19M
0M
-20M
0M
-
0M
0M
14M
3M
11M
-14M
0M
-13M
0M
-13M
32.79%
14M
1M
-13M
0M
-14M
0M
-
0M
0M
15M
4M
11M
-15M
0M
-15M
0M
-15M
32.79%
15M
1M
-14M
0M
-15M
1M
-
0M
0M
18M
3M
15M
-17M
0M
-17M
0M
-17M
32.79%
0M
0M
0M
0M
0M
0M
-
0M
0M
15M
3M
12M
-15M
0M
-15M
0M
-15M
32.79%
15M
0M
-15M
0M
-15M